Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Total Liabilities for 10 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 29.33% to $1.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a 29.33% increase, with the full-year FY2025 number at $1.6 billion, up 29.33% from a year prior.
  • Total Liabilities was $1.6 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.6 billion in Q4 2025 to a low of $540.3 million in Q2 2021.
  • A 5-year average of $1.0 billion and a median of $1.2 billion in 2023 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 177.67% in 2021; the steepest drop was 12.95% in 2021.
  • Ultragenyx Pharmaceutical's Total Liabilities stood at $599.8 million in 2021, then soared by 98.88% to $1.2 billion in 2022, then grew by 1.9% to $1.2 billion in 2023, then grew by 2.09% to $1.2 billion in 2024, then rose by 29.33% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Total Liabilities are $1.6 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).